

Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP

NCT06398873

Status RECRUITING
Sponsor Medical University of Vienna
Enrollment 80 participants

Key Eligibility Criteria

Inclusion (7)

- years of age
- Willingness to participate in the study
- Suffer from chronic rhinosinusitis defined as in EPOS 2020 criteria, see main text
- Group 1 (n=20, CRSsNP): Absence of nasal polyps
- Group 2 (N=60, CRSwNP): Presence of nasal polyps as confirmed by endoscopy or CT and planned therapy with dupilumab
- ... and 2 more (see full listing online)

Exclusion (8)

- Pregnancy (as determined by β -HCG test) or breast feeding
- Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity
- Patients with cystic fibrosis or primary ciliary dyskinesia
- Patients with permanent immunosuppression
- A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- ... and 3 more (see full listing online)

Locations (1 total)

Medical University of Vienna, Vienna, Austria, Austria

<https://clinicaltrials.gov/study/NCT06398873>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.